|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.9 HKD | -0.14% |
|
+27.14% | -28.92% |
| Apr. 12 | Keymed Biosciences Advances Solid Tumors Drug With First Patient Study | MT |
| Mar. 27 | KeyMed Biosciences’ Attributable Loss Widens in 2023 | MT |
Keymed Biosciences Inc. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 327.12 million compared to CNY 100 million a year ago. Net income was CNY 46.97 million compared to CNY 5.45 million a year ago.
Basic earnings per share from continuing operations was CNY 0.18 compared to CNY 0.0208 a year ago. Diluted earnings per share from continuing operations was CNY 0.18 compared to CNY 0.0204 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -28.92% | 1.23B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
KEYMED BIOSCIENCES INC. 
